Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.

ConditionsVenous Thromboembolism Obese Patients

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

About this trial

To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity

Eligibility criteria

Qualifiers

BMI >40 kg/m2

indication to primary or secondary thromboprophylaxis (Padua Score > 4), as clinical practice

Disqualifiers

creatinine clearance <30 mL/min (based on Cockcroft-Gault equation using adjusted body weight),

pregnant women,

low platelet count (<50.000/microL or <100.000/microL plus additional risk factors for bleeding),

active bleeding,

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Lead sponsor

Source ClinicalTrials.gov